Despite missing out on an FDA approval for major depressive disorder, Zurzuvae appears to be a strong asset for Sage Therapeutics, with high growth potential in 2024.

Related Keywords

Massachusetts , United States , Barry Greene , , Sage Therapeutic , Resume , Careers , Age Touts Strong Launch For Postpartum Depression Drug Zurzuvae , Iospace , Advice ,